What level of antibody affinity do you require? What will your project’s final application be? Do you have any limits in terms of time or money? If you’re deciding between Hybridoma Technology Steps and phage display for a monoclonal antibodies production project in India, these are some factors to consider.
This Blog Post Showcases The Essential Advantages Of Both Procedures To Assist You That Which Way Is Best For You:-
Hybridoma
George Köhler and César Milstein developed hybridoma generation for the first time in 1975, and it works by fusing immunized B spleen cells from mice with myeloma cells. The immortal B cells that produce the desired antibody are then chosen, and the best clones are screened to produce monoclonal antibodies with the desired antigen affinity.
Hybridoma Technology Steps are a more traditional way of producing monoclonal antibodies since it allows for producing extremely sensitive binders at a reasonable cost. Because of their excellent specificity, they’re well-suited to assay development. It’s also worth noting that the cells’ mammalian origin integrates post-translational alterations in vivo, lowering the chance of aggregation or recognition failures.
These traits suggest that hybridomas could be useful in creating therapeutic antibodies; however, there are also substantial disadvantages to employing hybridomas for this purpose.
To begin with, the hybridoma technology steps are lengthy: it takes an average of 6 to 8 months to acquire a sufficient number of monoclonal antibodies (against a few weeks for phage display). Second, the antibodies’ murine origin necessitates further humanization for therapeutic purposes, which adds to the cost. As a result, hybridoma development is gradually being substituted by faster, more appropriate biotherapeutic development procedures.
Advantages of Hybridoma
- Large scale production
- High antibody yield
- High specificity
- High antibody sensitivity
- Lower cost
Phage Display
For drug research on Monoclonal Antibodies In India, phage display-based monoclonal antibody manufacturing is an alternative to hybridoma technology.
Smith is credited with inventing the antibody phage display technology in 1985, with a gene coding for a specific antibody incorporated into the DNA sequence of a filamentous bacteriophage, allowing it to be expressed on the bacteriophage capsid’s surface. This distinction creates a relationship between the genotype and the phenotype. The phage infects Escherichia coli and uses its replication machinery to display new phage constantly without harming the host cell, as this permits large-scale antibody manufacturing in a short amount of time.
Screening procedures can be used to create a library of naive or immune phages that can be utilized to detect an antigen-antibody interaction of interest. Libraries can be made from any animal, including humans, allowing for direct screening of human antibodies. Because the genotype and phenotype are linked, it’s also simple to get immediate access to the sequence, making additional engineering or recombinant protein manufacturing easier for the Phage Display Antibody Library.
Advantages of Phage Display
- Large scale production
- Fast process
- Great control over the selection process
- It’s easy to screen a large number of different clones.
- Possible to directly screen human libraries
- Possible to screen toxic antigens
- No immunogenicity issue (for naïve libraries)
- No clone viability issues
- Direct access to sequence
- No animal use (for naïve libraries)
Conclusion
It would be best to look at the advantages of each method discussed above to choose which display strategy, monoclonal antibodies India, is best for your needs.
GeNext Genomics has developed a unique phage display antibody library to create high-affinity monoclonal antibodies and has experience using the technology for a variety of service projects. In order to successfully satisfy your specific requirements, GNG can provide high-quality bespoke Phage Display Antibody Library screening services.
The Antibody Library can be used to find antibodies for drug development, diagnostics, and immunohistochemistry. For a better understanding, don’t hesitate to get in touch with us at info@genextgenomics.com, as one of our technical experts will contact you to discuss your needs thoroughly.